DrugBank

MARCH 22, 2024

There are many obstacles that you have to overcome on the road to success in early-stage drug discovery and drug repurposing research. As a result, the industry is turning to managed data sources and are having to weigh the costs and benefits of open data sources versus enterprise research tools.

Licensing 74

Licensing Licensing Research Production 74

Advarra

AUGUST 16, 2022

Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. These centers, in conjunction with the FDA and U.S.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

MAY 19, 2023

HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023 Regeneron Pharmaceuticals, Inc. Using her research, she says she found the smallest of these planets ever discovered. Kaitlyn Wang won first place and received the $75,000 George D.

Engineering 52

Engineering International Science Virus 52

Codon

JANUARY 21, 2024

When a vaccine fails, that can have downstream effects on how other researchers in the field approach their own vaccine development, and how funding gets moved around. If a Shigella vaccine fails, researchers save a lot of money by not testing it in the field and having it fail there. But it's hard to find the counterfactual.

Vaccine 108

Vaccine Trials Disease Treatment 108

Agency IQ

JUNE 9, 2023

What will the orphan drug market exclusivity haircut mean for industry? Just over a month ago, the European Commission released its proposal for the new pharmaceutical directive and regulation. Additionally, the smaller potential customer base may provide an insufficient return on the investment into research. member states.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

The Pharma Data

NOVEMBER 10, 2020

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. Yong-Jun Liu , the newly appointed President of Innovent also made his first public appearance on the virtual R&D day.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Agency IQ

AUGUST 2, 2024

Positive August 2024 Eurneffy (epinephrine) Ars Pharmaceuticals Irl Limited Positive August 2024 MResvia (Respiratory Syncytial Virus mRNA vaccine) Moderna Biotech Spain S.L. Positive August 2024 Balversa (erdafitinib) Janssen-Cilag International N.V.

Regulations 40

Regulations Clinical Trials Production Trials 40

Drug Target Review

APRIL 17, 2023

Featured within this ebook are in-depth application notes as well as the latest research from leading academics and pharmaceutical companies, including: Anders Bach, Associate Professor at the Department of Drug Design and Pharmacology at the University of Copenhagen Researchers from the Francis Crick Institute and GlaxoSmithKline , Dr Andrew Powell, (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Laboratories Drugs Drug Research 52

Agency IQ

AUGUST 11, 2023

BY KARI OAKES AUG 7, 2023 10:20 PM CDT Quick background on nitrosamines in pharmaceutical products Nitrosamines are a large and diverse class of chemicals, with more than 300 different structurally distinct species known today. In 2018, NDMA was first detected in the active pharmaceutical ingredient (API) for valsartan, a blood pressure drug.

FDA 40

FDA Science Production Regulations 40

Agency IQ

NOVEMBER 27, 2023

In recent years, nitrosamines, and most commonly N-nitrosodimethylamine (NDMA), have been found in finished drug products in several classes, including medicines used for diabetes, hypertension, acid reflux, and smoking cessation. [ In a study of more than 12,000 small molecule drugs , researchers found 40.4%

Regulations 40

Regulations Production FDA Packaging 40